• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arvinas Inc. (Amendment)

    2/13/24 8:14:06 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email
    SC 13G/A 1 d10980586_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.2)

     

     

    Arvinas, Inc.
    (Name of Issuer)

     

     

    common stock, $0.001 par value per share
    (Title of Class of Securities)

     

     

    04335A105
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,985,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,985,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,985,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.4%  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     
     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,985,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,985,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,985,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners Fund (GP) LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,985,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,985,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,985,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     
     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,985,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,985,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,985,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Master Fund LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,140,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,140,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,140,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      3.1%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     
     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      David Witzke  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,985,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,985,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,985,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.4%  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

     
     

     

    CUSIP No. 04335A105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Gregory  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,985,117  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,985,117  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
       2,985,117  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.4%  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

     

     

     
     

     

    Item 1. (a). Name of Issuer:  
           
        Arvinas, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    395 Winchester Ave.

    5 Science Park

    New Haven, CT 06511

    United States of America

     

     

    Item 2. (a). Name of person filing:  
           
       

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    David Witzke

    Michael Gregory

     

     

      (b). Address or principal business office or, if none, residence:  
           

       

    Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Partners Management (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners Fund (GP) LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Master Fund LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    David Witzke

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

    Michael Gregory

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

      (c). Citizenship:  
           
       

    Avidity Partners Management LP– Delaware

    Avidity Partners Management (GP) LLC – Delaware

    Avidity Capital Partners Fund (GP) LP – Delaware

    Avidity Capital Partners (GP) LLC – Delaware

    Avidity Master Fund LP – Cayman Islands

    David Witzke – United States of America

    Michael Gregory – United States of America

     

     

      (d).   Title of class of securities:  
           
        common stock, $0.001 par value per share  

     

      (e). CUSIP No.:  
           
        04335A105  

     

     
     

     

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
       

    Avidity Partners Management LP: 2,985,117

    Avidity Partners Management (GP) LLC: 2,985,117

    Avidity Capital Partners Fund (GP) LP: 2,985,117

    Avidity Capital Partners (GP) LLC: 2,985,117

    Avidity Master Fund LP: 2,140,117

    David Witzke: 2,985,117

    Michael Gregory: 2,985,117

     

      (b) Percent of class:
         
       

    Avidity Partners Management LP: 4.4%

    Avidity Partners Management (GP) LLC: 4.4%

    Avidity Capital Partners Fund (GP) LP: 4.4%

    Avidity Capital Partners (GP) LLC: 4.4%

    Avidity Master Fund LP: 3.1%

    David Witzke: 4.4%

    Michael Gregory: 4.4%

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

    ,

             
        (ii)   Shared power to vote or to direct the vote

    Avidity Partners Management LP: 2,985,117

    Avidity Partners Management (GP) LLC: 2,985,117

    Avidity Capital Partners Fund (GP) LP: 2,985,117

    Avidity Capital Partners (GP) LLC: 2,985,117

    Avidity Master Fund LP: 2,140,117

    David Witzke: 2,985,117

    Michael Gregory: 2,985,117

     
             
        (iii) Sole power to dispose or to direct the disposition of

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

    ,

             

        (iv)   Shared power to dispose or to direct the disposition of

    Avidity Partners Management LP: 2,985,117

    Avidity Partners Management (GP) LLC: 2,985,117

    Avidity Capital Partners Fund (GP) LP: 2,985,117

    Avidity Capital Partners (GP) LLC: 2,985,117

    Avidity Master Fund LP: 2,140,117

    David Witzke: 2,985,117

    Michael Gregory: 2,985,117

     

    .

             

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
     
     
       

     

     
     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

      

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A

     

    Item 9. Notice of Dissolution of Group.

      

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

      

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

     

    February 14, 2024

      (Date)
       
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/ David Witzke
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
       
     

    Michael Gregory

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/Michael Gregory
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

     

    Exhibit 1

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock of Arvinas, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing

     The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of February 14, 2024.

           
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

     

    /s/ David Witzke

     
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
         
      Michael Gregory
      Avidity Partners Management LP
      Avidity Partners Management (GP) LLC
      Avidity Capital Partners Fund (GP) LP
     

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

         
      By:  /s/ Michael Gregory  
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))

     

     

    Get the next $ARVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARVN

    DatePrice TargetRatingAnalyst
    5/5/2025$11.00Buy → Hold
    Truist
    5/2/2025$10.00Buy → Hold
    Jefferies
    5/2/2025Buy → Hold
    TD Cowen
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    3/12/2025$57.00 → $12.00Outperform → Neutral
    Wedbush
    3/11/2025Outperform → Perform
    Oppenheimer
    12/10/2024$69.00Buy
    BTIG Research
    11/18/2024$55.00Overweight
    Stephens
    More analyst ratings

    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to

      4/28/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

      – ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is

      4/28/25 6:45:37 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Berkowitz Noah sold $74,372 worth of shares (8,658 units at $8.59), decreasing direct ownership by 7% to 110,023 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      3/19/25 8:06:56 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Loomis David K sold $20,334 worth of shares (1,214 units at $16.75), decreasing direct ownership by 6% to 18,863 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      2/25/25 6:37:50 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cacace Angela M sold $70,238 worth of shares (4,207 units at $16.70), decreasing direct ownership by 4% to 97,231 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      2/25/25 6:35:35 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Financials

    Live finance-specific insights

    See more
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to

      4/28/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – –

      2/11/25 7:00:04 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

      7/30/24 7:00:00 AM ET
      $ARVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

      - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive

      6/24/24 4:37:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arvinas downgraded by Truist with a new price target

      Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00

      5/5/25 8:28:44 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by TD Cowen

      TD Cowen downgraded Arvinas from Buy to Hold

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Jefferies with a new price target

      Jefferies downgraded Arvinas from Buy to Hold and set a new price target of $10.00

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Arvinas Inc.

      10-Q - ARVINAS, INC. (0001655759) (Filer)

      5/1/25 5:16:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - ARVINAS, INC. (0001655759) (Filer)

      5/1/25 7:05:21 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.

      SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)

      4/30/25 10:58:51 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 1:22:38 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 7:00:23 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      9/10/24 10:30:07 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care